CYTKCytokinetics, Incorporated

$8B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+318.1% YoY

Gross Profit

-$743,000-38.4% margin

Operating Income

-$167M-8613.4% margin

Net Income

-$306M-15815.0% margin

EPS (Diluted)

$-2.55

QoQ Revenue Growth

-97.1%

Cash Flow

Operating Cash Flow

-$108M

Free Cash Flow

-$117M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$2.0B

Stockholders' Equity

-$521M

Cash & Equivalents

$225M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$463,000	+318.1%
Gross Profit	-$743,000	-$84M	+99.1%
Operating Income	-$167M	-$141M	-18.4%
Net Income	-$306M	-$161M	-90.7%

Revenue Segments

Collaboration Revenues

$2M100%

Geographic Segments

CHINA

$400,000100%

CYTK Q3 2025 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena